Previous close | 2.7500 |
Open | 2.7500 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 2.7500 - 2.7500 |
52-week range | 2.3500 - 6.1000 |
Volume | |
Avg. volume | 196 |
Market cap | 94.402M |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248), a drug candidate for the treatment of systemic sclerosis, has been granted Orphan Drug Designation in the US by the Food and Drug Administration (FDA).
Election of the board of directors and auditor